Our writer can see the appeal of this recently popular dividend stock from the FTSE 100 index. But will he buy it for his own ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

The best metric is not weight, but a particularly toxic kind of fat.

U.S. stocks soared Monday as investors celebrated major progress on a U.S.-China trade deal. The Dow added over 1,100 points, ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...